NCT06046248View on ClinicalTrials.gov

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG

Belumosudil

200mg PO QD x 24 cycles (28-day cycle)

DRUG

Rituximab

375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses

Trial Locations (1)

30342

RECRUITING

Northside Hospital, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Northside Hospital, Inc.

OTHER

NCT06046248 - Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease | Biotech Hunter | Biotech Hunter